| 7465732 |
(2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives |
David W. Piotrowski |
2008-12-16 |
$587,110,000 |
| 7291618 |
Therapeutic compounds |
David W. Piotrowski |
2007-11-06 |
$219,431,000 |
| 6846820 |
Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors |
Dennis J. Hoover, William H. Martin, Judith Treadway |
2005-01-25 |
$158,531,000 |
| 6812350 |
Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds |
— |
2004-11-02 |
$200,692,000 |
| 6710040 |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
Janice Parker |
2004-03-23 |
$279,730,000 |
| 6649634 |
Substituted N-( indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
Dennis J. Hoover, William H. Martin, Judith Treadway |
2003-11-18 |
$153,763,000 |
| 6541495 |
Carboxylic acid derivatives as inhibitors of hyperproliferation diseases |
Steven Wayne Goldstein, Kelly P. Longo |
2003-04-01 |
$432,043,000 |
| 6297269 |
Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
Dennis J. Hoover, Judith Treadway, William H. Martin |
2001-10-02 |
$475,381,000 |
| 6277877 |
Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors |
Dennis J. Hoover, William H. Martin, Douglas Phillips, Judith Treadway |
2001-08-21 |
$497,480,000 |
| 6107329 |
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
Dennis J. Hoover, William H. Martin, Douglas Phillips, Judith Treadway |
2000-08-22 |
$440,456,000 |
| 5998463 |
Glycogen phosphorylase inhibitors |
Reinhard Sarges |
1999-12-07 |
$328,785,000 |
| 5498621 |
Oxazolidinedione hypoglycemic agents |
Robert L. Dow, David A. Clark |
1996-03-12 |
$31,099,000 |
| 5438074 |
3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
— |
1995-08-01 |
$151,106,000 |
| 5401761 |
Thiazolidinedione hypoglycemic agents |
Steven Wayne Goldstein |
1995-03-28 |
$113,541,000 |
| 5330998 |
Thiazolidinedione derivatives as hypoglycemic agents |
David A. Clark, Steven Wayne Goldstein |
1994-07-19 |
$54,908,000 |
| 5306726 |
3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
— |
1994-04-26 |
$36,919,000 |
| 5232945 |
3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
— |
1993-08-03 |
$31,631,000 |
| 5223522 |
Thiazolidinedione hypoglycemic agents |
David A. Clark, Steven Wayne Goldstein, Gerald F. Holland, James P. Rizzi |
1993-06-29 |
$132,799,000 |
| 5130379 |
Hypoglycemic thiazolidinedione derivatives |
David A. Clark, Steven Wayne Goldstein |
1992-07-14 |
$46,302,000 |
| 5120754 |
Thiazolidinedione hypoglycemic agents |
David A. Clark, Steven Wayne Goldstein, Gerald F. Holland, James P. Rizzi |
1992-06-09 |
$31,105,000 |
| 5089514 |
3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
— |
1992-02-18 |
$31,714,000 |
| 5061717 |
Thiazolidinedione hypoglycemic agents |
David A. Clark, Steven Wayne Goldstein, Gerald F. Holland, James P. Rizzi |
1991-10-29 |
$39,814,000 |
| 5036079 |
Hypoglycemic thiazolidinedione derivatives |
David A. Clark, Steven Wayne Goldstein |
1991-07-30 |
$16,583,000 |
